Global Oncolytic Virus Immunotherapy Market (2020 to 2026) - Dosage, Price & Clinical Trials Outlook - ResearchAndMarkets.com

·5-min read

The "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" report has been added to ResearchAndMarkets.com's offering.

As per this reports findings, it is estimated that the total inflation of the market with respect to clinical platform, wider acceptance in a short period of time will drive the market in the upcoming years.

A gradual increase in the interest of the researchers towards oncolytic virus therapy will develop the market which will eventually bring complete revolution in terms of applications to the cancer patients. The future market insight for the therapy is analyzed to provide unlimited number of trends and opportunities, leading to aggregation of all the cancer related bio-pharmaceutical companies and research centers towards the further development and commercialization of the therapy.

Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026 Report Highlights:

  • Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity

  • Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials

  • USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials

  • Comprehensive Insight on Clinical & Non Clinical Issues Related to Global Oncolytic Virus Immunotherapy Market Development

  • Approved Oncolytic Virus Immunotherapy: 2

  • Global Research Progress & Medical Advancement Insight

  • Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight

Companies Mentioned

  • BioVex Inc.

  • Cell Genesys

  • Crusade Laboratories

  • Genelux Corporation

  • Jennerex Biotherapeutics

  • Lokon Pharma

  • Merck

  • MultiVir

  • Oncolys BioPharma

  • Oncolytics Biotech

  • Oncos Therapeutics (Targovax)

  • PsiOxus Therapeutics

  • Shanghai Sunway Biotech

  • Takara Bio

  • VCN Biosciences

  • ViroTarg

  • Vyriad

Increase in prevalence and mortality rate associated with cancer has always remained a challenge to the modern medicine with respect to the development of more reliable therapies. In the past few years, one of the greatest breakthrough novel cancer therapy that has been developed by the researchers is the oncolytic virus immunotherapy. The overall procedure of the therapy is based on the ability of the oncolytic virus to infect and further lyse the tumor cells by boosting the immune system of the patient. Some of the virus strains that have been tested and proved to be adding to the various applications of the therapy are canine distemper virus, adenovirus, vaccinia virus and reovirus in the preclinical and clinical studies.

The undefined applications of using virus for the cancer treatment and the in-vitro manipulation of the virus with respect to cancer micro environment are estimated to be providing successful clinical outcomes at preclinical and clinical level, thus leading to the enhancement and the expansion of the market. All the clinical trials associated with the therapy are boosted with the available drivers as all concerned drivers are estimated to bring forward numerous opportunities for the cancer patients. The market concerned with the growth of the oncolytic virus therapy is also focused on increasing the research and development sector activities. The market within no time is estimated to be recognized as an important asset for the cancer therapeutics as it carries the ability to change the stringent cancer treatment paradigm available for the patients. The current clinical platform is estimated to be developing a competitive landscape for the other cancer markets as it is getting fragmented at a high speed when compared with other cancer therapies status.

Key Topics Covered:

1. Introduction to Oncolytic Virus

2. Primer of Virotherapy in Malignancies

3. Viral Oncolysis Mechanism of Action

4. Oncolytic Viruses Immunotherapy Overview

4.1 Stimulation of Antitumor Immune Responses

4.2 Oncolytic Viruses as Cancer Vaccines

5. Varieties of Viruses Casted as Oncolytic Viruses

5.1 Oncolytic Wild Type Viruses

5.1.1 Reovirus (Respiratory Enteric Orphan Virus)

5.1.2 Vesicular Stomatitis Virus (VSV)

5.1.3 Newcastle Disease Virus (NDV)

5.1.4 Myxoma

5.2 Genetically Engineered Oncolytic Viruses

5.2.1 Adenoviruses

5.2.2 Herpes Simplex Virus

5.2.3 Vaccinia Virus

6. Potential Oncolytic Virus Immunotherapy for Cancers

6.1 Breast Cancer

6.2 Lung Cancer

6.3 Prostate Cancer

6.4 Melanoma

6.5 Brain Tumor

6.6 Blood Cancer

7. Global Oncolytic Virus Immunotherapy Therapy Market Overview

7.1 Preface towards Oncolytic Virus Arcade

7.2 Market Aspects of Approved Oncolytic Viruses

8. Oncolytic Virus Immunotherapy Clinical Pipeline Overview

8.1 By Phase

8.2 By Company

8.3 By Country

8.4 By Indication

8.5 By Patient Segment

9. Global Oncolytic Virus Immunotherapy - Availability, Dosage & Price Analysis

9.1 Imlygic (Talimogene laherparepvec)

9.2 Oncorine (H101)

10. Research Progress & Medical Advancement in Oncolytic Virus Therapy Market

10.1 Oncolytic Virus Therapy Development as a Cancer Vaccine

10.2 Oncolytic Virus Therapy Collaboration with T-Cell Therapy for Advanced Results

10.3 Preliminary Effectiveness of Oncolytic Virus Therapy in Killing Malignant Tumor Cells in Children

10.4 Combined Study of Oncolytic Virus Therapy and CAR-T Cell Therapy by City of Hope Researchers

10.5 TG4001 & TG6002 Positive Clinical Results against HPV-Induced Cancers

10.6 Pelareorep-Anti-PD-1 Combination for the Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer

10.7 Adenovirus E3 Region to Substantially Improve Oncolytic Efficacy & Potency

10.8 University of Helsinki Novel Solution for Advancing Oncolytic Virus Therapy

10.9 Valo Therapeutics Technology Acquisition for Advancing Oncolytic Therapy

10.10 Mayo Clinic to Expand Oncolytic Virus Therapy against Multiple Myeloma

11. Strategic Partnership & Collaborations to Advance the Oncolytic Virus Therapy Market

12. Global Oncolytic Virus Immunotherapy Clinical Trials By Company, Indication & Phase

13. Marketed Oncolytic Virus Immunotherapy Clinical Insight

13.1 IMLYGIC

13.2 Oncorine

14. Global Oncolytic Virus Immunotherapy Market Dynamics

14.1 Market Drivers

14.2 Growth Inhibitors

15. Global Oncolytic Virus Immunotherapy Market Future Outlook

16. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/da1egn

View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005713/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900